A REVIEW OF ANALYTICAL METHODS FOR ESTIMATION OF LEVOCETIRIZINE AND MONTELUKAST SODIUM IN COMBINED PHARMACEUTICAL DOSAGE FORMS
AbstractBeginning from simple analytical methods to the recent development of advanced hyphenated techniques stages, various analytical methods have been designed for the multicomponent analysis of drugs. Simultaneous estimation of drugs in the combined dosage form is vital in the pharmaceutical analysis since it is cost-effective and time-saving. Levocetirizine, the R-enantiomer of Cetirizine, is a peripheral H1-receptor antagonist used as a non-sedative antihistamine in treating chronic idiopathic urticaria, angioedema, and allergic rhinitis. Montelukast Sodium is selective cysteinyl leukotriene I receptor inhibitor that acts as an anti-asthmatic agent in the bronchial tubes and lungs. The combination of Levocetirizine with Montelukast Sodium in the pharmaceutical formulation is frequently used in the treatment of Allergic rhinitis as it has been shown to have additional benefits to the patients in reducing the symptoms efficiently. This review article has compared and addressed a variety of analytical methods applied for estimating Levocetirizine and Montelukast Sodium in the combined dosage form. The methods include UV Spectrophotometry methods, High-Performance Liquid Chromatography (HPLC), Ultra Performance Liquid Chromatography (UPLC), and High-Performance Thin-layer Chromatography (HPTLC). This review article also gives us insight into the development of different analytical techniques for estimating Levocetirizine and Montelukast Sodium combined with other drugs available in the market. The present paper suggests a suitable method for analyzing this pharmaceutical compound and helps optimize various analytical methods for their determination.
Article Information
8
4871-4884
822 KB
837
English
IJPSR
Y. D. Bhutia, N. R. Bhuyan, B. Shrestha and V. R. Baraily *
Department of Pharmaceutical Analysis, Himalayan Pharmacy Institute, Majhitar, East Sikkim, India.
Vishalahpi21@gmail.com
26 March 2022
24 June 2022
13 September 2022
10.13040/IJPSR.0975-8232.13(12).4871-84
01 December 2022